Patents by Inventor Ryan P. LARSON
Ryan P. LARSON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240158837Abstract: Provided herein are methods of identifying genomic region(s) predictive of an outcome of treatment with a cell therapy and/or of a phenotype of function of the cells. In some embodiments, the methods include epigenetic and/or epigenomic analyses of the cells in connection with methods for preparing engineered cells for cell therapy and/or predicting response to a cell therapy, e.g., engineered cells for cell therapy. In some embodiments, the methods include steps to assess, characterize and analyze changes or modifications in an epigenetic property of gene region or regions, such as chromatin accessibility, nucleosome occupancy, histone modification, spatial chromosomal conformation, transcription factor occupancy and/or DNA methylation. In some embodiments, the epigenetic and/or epigenomic analysis includes determining the epigenetic properties of a cell, e.g., an engineered cell for cell therapy.Type: ApplicationFiled: October 17, 2023Publication date: May 16, 2024Applicant: Juno Therapeutics, Inc.Inventors: Mark L. BONYHADI, David G. KUGLER, Timothy G. JOHNSTONE, Ronald James HAUSE, Jr., Lucas J. THOMPSON, Ryan P. LARSON
-
Publication number: 20240123699Abstract: Methods and systems are disclosed for apparel assembly using three-dimensional printing directly onto fabric apparel materials. Disclosed is a method and system for direct three-dimensional printing and assembly of an article of apparel, including designing a three-dimensional pattern for printing, positioning at least a portion of the article on a tray in a three-dimensional printing system, the portion being positioned substantially flat on the tray, printing a three-dimensional material directly onto the article using the designed pattern, curing the printed material, and removing the article from the three-dimensional printing system.Type: ApplicationFiled: December 20, 2023Publication date: April 18, 2024Applicant: NIKE, Inc.Inventors: David P. Jones, Ryan R. Larson
-
Publication number: 20240053250Abstract: Provided are methods for flow cytometry analysis, including the setting and use of static gating thresholds separating positive fluorescence from negative fluorescence for each fluorescence channel in the assay.Type: ApplicationFiled: December 15, 2021Publication date: February 15, 2024Applicant: Juno Therapeutics, Inc.Inventors: Rebecca BRUNETTE, Ryan P. LARSON, Kevin HAWKINS
-
Patent number: 11821027Abstract: Provided herein are methods of identifying genomic region(s) predictive of an outcome of treatment with a cell therapy and/or of a phenotype of function of the cells. In some embodiments, the methods include epigenetic and/or epigenomic analyses of the cells in connection with methods for preparing engineered cells for cell therapy and/or predicting response to a cell therapy, e.g., engineered cells for cell therapy. In some embodiments, the methods include steps to assess, characterize and analyze changes or modifications in an epigenetic property of gene region or regions, such as chromatin accessibility, nucleosome occupancy, histone modification, spatial chromosomal conformation, transcription factor occupancy and/or DNA methylation. In some embodiments, the epigenetic and/or epigenomic analysis includes determining the epigenetic properties of a cell, e.g., an engineered cell for cell therapy.Type: GrantFiled: January 10, 2018Date of Patent: November 21, 2023Assignee: Juno Therapeutics, Inc.Inventors: Mark L. Bonyhadi, David G. Kugler, Timothy G. Johnstone, Ronald James Hause, Jr., Lucas J. Thompson, Ryan P. Larson
-
Publication number: 20220008465Abstract: Provided are methods for treatment and uses involving the administration of doses of engineered T cells for treating subjects with disease and conditions such as certain B cell malignancies, and related methods, compositions, uses and articles of manufacture. The engineered cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the disease or condition is acute lymphoblastic leukemia (ALL) or non-Hodgkin lymphoma (NHL). In some embodiments, the subject is within a particular range of age, such as subjects that are 25 years or less of age, such as pediatric subjects.Type: ApplicationFiled: November 15, 2019Publication date: January 13, 2022Applicant: Juno Therapeutics, Inc.Inventors: Nikolaus Sebastian TREDE, Tina ALBERTSON, Brian CHRISTIN, Rachel K. YOST, Michelle KANG, Ryan P. LARSON, Jeffrey TEOH
-
Publication number: 20210128616Abstract: Provided are methods, compositions and articles of manufacture for use in cell therapy involving the administration of one or more doses of a therapeutic T cell composition, and methods, compositions and articles of manufacture for use in the same. The cells of the T cell composition express recombinant receptors such as chimeric receptors, e.g. chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the embodiments of the present disclosure, including the dose of cells or units of cells administered and/or the phenotype of administered cells, provide various advantages, such as consistent dosing, lower risk of toxicity and/or increased response in subjects administered the T cell compositions.Type: ApplicationFiled: December 7, 2018Publication date: May 6, 2021Applicant: Juno Therapeutics, Inc.Inventors: Kedar Himanshu DAVE, Todd DEVRIES, Ronald James HAUSE, Jr., Ryan P. LARSON, Christopher Glen RAMSBORG, Claire L. SUTHERLAND, Nathan K. YEE, Rachel K. YOST
-
Publication number: 20200354677Abstract: The present disclosure provides methods for genetically engineering T cells, such as CD4+ T cells, for use in cell therapy. In some aspects, the provided methods include one or more steps for incubating the cells under stimulating conditions, introducing a recombinant polypeptide to the cells through transduction or transfection, and cultivating the cells under conditions that promote proliferation and/or expansion. In some aspects, the incubation and/or the cultivation is performed in the presence of recombinant IL-2. In some aspects, the provided methods are an efficient, reliable means to produce genetically engineered T cells with a high degree of success.Type: ApplicationFiled: October 31, 2018Publication date: November 12, 2020Applicant: Juno Therapeutics, Inc.Inventors: Sarah Y. LEE, Pascal BEAUCHESNE, Mark L. BONYHADI, Ryan L. CRISMAN, Ryan P. LARSON, Mary MALLANEY, Christopher Glen RAMSBORG, Clinton WEBER, John Matthew WESNER, Nathan YEE
-
Publication number: 20200191774Abstract: Provided herein are methods, compositions and articles of manufacture for use in connection with cell therapy involving the administration of one or more doses of a therapeutic T cell composition. The cells of the T cell composition express recombinant receptors such as chimeric receptors, e.g. chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the provided embodiments, including the numbers of cells or units of cells administered and/or the potency of administered cells, provide various advantages, such as lower risk of toxicity in subjects administered the T cell compositions.Type: ApplicationFiled: February 27, 2018Publication date: June 18, 2020Applicant: Juno Therapeutics, Inc.Inventors: Brian CHRISTIN, Michael Gerard COVINGTON, Kedar Himanshu DAVE, Richard James GETTO, Jr., Tom KOWSKI, Ryan P. LARSON, Christopher Glen RAMSBORG, Nikolaus Sebastian TREDE, Clinton WEBER, James Boyd WHITMORE, Nathan YEE, Pascal BEAUCHESNE, Travis BECKETT, Samuel Charles BLACKMAN, Nathaniel CHARTRAND, Mel DAVIS-PICKETT, Mark GILBERT, Nathaniel LAMBERT, He LI, Mary MALLANEY, Kathryn Lindsay POLLOCK, Valerie ODEGARD, Jeff SMITH, Claire SUTHERLAND, Andrew W. WALKER